As of 2025-08-07, the Intrinsic Value of Panacea Biotec Ltd (PANACEABIO.NS) is 52.38 INR. This PANACEABIO.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 404.35 INR, the upside of Panacea Biotec Ltd is -87.00%.
The range of the Intrinsic Value is 44.09 - 67.06 INR
Based on its market price of 404.35 INR and our intrinsic valuation, Panacea Biotec Ltd (PANACEABIO.NS) is overvalued by 87.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 44.09 - 67.06 | 52.38 | -87.0% |
| DCF (Growth 10y) | 50.83 - 76.04 | 60.03 | -85.2% |
| DCF (EBITDA 5y) | 101.17 - 172.41 | 135.38 | -66.5% |
| DCF (EBITDA 10y) | 92.26 - 162.44 | 124.22 | -69.3% |
| Fair Value | -34.16 - -34.16 | -34.16 | -108.45% |
| P/E | (16.07) - 9.48 | (14.53) | -103.6% |
| EV/EBITDA | 4.74 - 153.29 | 73.42 | -81.8% |
| EPV | 41.78 - 48.81 | 45.30 | -88.8% |
| DDM - Stable | (8.69) - (19.67) | (14.18) | -103.5% |
| DDM - Multi | 20.53 - 37.05 | 26.51 | -93.4% |
| Market Cap (mil) | 24,766.44 |
| Beta | 2.20 |
| Outstanding shares (mil) | 61.25 |
| Enterprise Value (mil) | 23,918.84 |
| Market risk premium | 8.31% |
| Cost of Equity | 12.63% |
| Cost of Debt | 13.93% |
| WACC | 12.60% |